Natco Pharma Limited has informed the Exchange regarding a press release dated November 21, 2025, titled "Conclusion of FDA Inspection at our Manali, Chennai API Unit".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Smallcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma has disclosed a press release dated November 21, 2025, informing the exchange that an FDA inspection at its API (Active Pharmaceutical Ingredient) manufacturing facility in Manali, Chennai has concluded. The headline does not specify the outcome of the inspection, such as whether any observations (Form 483) were issued. The Manali API unit is one of Natco Pharma's key manufacturing facilities supplying active ingredients for its formulations business. Investors should look for follow-up disclosures or the full press release to understand whether the inspection was clean or raised compliance concerns.
FDA inspections are routine, but the conclusion without immediate mention of a warning letter or major adverse action is typically viewed as neutral to mildly positive. Watch for any follow-up filings detailing observations, as adverse FDA findings could impact API exports and future revenue from this facility.